This also drove even higher expression of CCL17, a major tumor infiltrating lymphocyte (TIL) attracting chemokine, and CCL24 a chemokine known to preferentially chemoattract M1 macrophages.10 These data highlight a novel and impactful role for adenosine pathway inhibition within chemotherapy/checkpoint inhibitor combinations. Here, CCL17 is linked to neoplasm.